Stock Down 66% and the HIMS CEO Says He's Loving It

Source: 20VC with Harry Stebbings | Published: 2026-04-04T14:00:03Z

HIMS slashed the price of blockbuster GLP-1 weight-loss drugs from $2,000 to $149 in just 18 months — a structural disruption nearly unprecedented in the U.S. pharmaceutical distribution system.

Going Public Is Boot Camp, Not the Finish Line

Dudum compares going public to boot camp: every 90 days you set ambitious targets, then push your team relentlessly to hit them. He believes staying private makes it too easy to get comfortable — worst case, a few VCs call to express their anxiety. Public markets force you to prove every quarter that you're advancing toward your ten-year vision.

He points to Google, Facebook, Apple, and Amazon: all went public within a few years of founding, and their founders were forced to learn growth, efficiency, and storytelling under the spotlight. HIMS went public just 36 months after incorporation — sounds insane, but Dudum thinks that was exactly the right tempo. His two prerequisites for founders considering an IPO: business predictability, and willingness to sign up for a ten- to twenty-year commitment.

He Hires for One Thing: Resilience

Dudum's CFO Yemi served as a division CFO at Uber during COVID — the business went to zero overnight, and he had to figure out how to survive. Chief Product Officer Dheerja lived through the GameStop chaos at Robinhood. Dudum says he specifically seeks out people who've been through crises.

When you're disrupting an industry, your team has to be comfortable being uncomfortable — comfortable navigating chaos, comfortable staying calm.

He thinks many founders make a critical mistake as they scale: they start hiring "more senior" people — polished résumés, impressive pedigrees, strategy types — because the company has reached a stage where it should "level up." Dudum made this mistake himself but kept arriving at the same conclusion: find people who love the mission, love getting their hands dirty, are tactically strong, and have been through adversity. Tony Xu at DoorDash maintains startup speed at an $80 billion scale because he built an operationally minded team.

Don't Be First. Be Best.

Every so often, HIMS gets labeled as "a [category] company." First it was "the ED company," then "the hair loss company," then "the weight loss company." Dudum says the next label will probably be "the peptides company." In reality, the platform spans over a dozen distinct clinical categories, each growing independently, and weight loss is far from the majority of revenue.

Early on, he made a big mistake: assuming more products on the platform was always better, so he invested in skincare and vitamin supplements — things you could buy across the street at Walgreens for roughly the same price. The category ceiling came fast; Facebook ad curves peaked and declined. That was his nightmare. The lesson: don't sell commodities. Sell things with real differentiation — pharmaceutical-grade quality, personalized treatment plans, products people can't easily get elsewhere.

When entering new categories like peptides, he doesn't rush to be first to market. He waits until clinical protocols are mature and supply chain quality is proven. Brand trust means that when you launch something, users know it's safe and validated.

The Core of Brand Marketing Is Consistency, Not Creativity

HIMS spends roughly $1 billion a year on marketing. Dudum says early on they blanketed the entire New York subway system with ads — the team was ecstatic, posting photos, celebrating. Then they looked at the data: maybe a tiny blip in New York that day, maybe not. These one-off brand activations feel great, cost a fortune, and deliver no business value.

His Chief Communications Officer Kathryn told him during her interview: the biggest brand mistake early-stage companies make is getting bored of the message and changing the subject. One podcast appearance pushes one vision; the next one pivots to something fresh. But great brands are great because everyone knows why they exist, who they serve, and what value they deliver — they repeat the same thing 20 different ways every single week. That takes enormous discipline and, frankly, is far more boring than dreaming up new ideas.

18 Months: A Blockbuster Drug's Price Drops 80%

GLP-1 weight loss drugs launched at around $2,000. Eighteen months later, GLP-1 pills on the HIMS platform were down to $149. Dudum believes this is virtually unprecedented in pharmaceutical history — a century-defining blockbuster drug dropping 80% in price in that timeframe.

What happened was a fundamental restructuring of distribution. In the traditional U.S. model, drugs pass through PBMs (pharmacy benefit managers) and insurers, each adding layers of markup, leaving consumers unable to make sense of the pricing. HIMS and consumers together applied enormous regulatory and market pressure until drugmakers agreed to sell directly to consumers at cash prices of $150–200. This was a structural shift in America's entire pharmaceutical distribution system, accomplished in 18 months.

Physical Infrastructure Is the Moat in the AI Era

Someone asked Dudum whether his biggest threat is OpenAI — ChatGPT is already many people's first stop for health questions, and extending into medical services seems like a natural next step. Dudum cited Dario Amodei's recent argument: in the AI era, the most defensible companies are those that do physical things.

HIMS treats tens of thousands of patients daily, employs thousands of licensed physicians, and operates roughly one million square feet of pharmacy fulfillment facilities staffed with pharmacists and robotic compounding equipment. What ChatGPT can do is massively expand the pool of people thinking about their health — that's an incremental funnel for HIMS, not an existential threat. The eventual relationship will likely resemble Google search ads: users express health needs in an AI conversation and get directed to platforms that can actually deliver professional care and medication.

One Drop of Blood, 50 Biomarkers, Nearly Free

Last year HIMS acquired YourBio Health, a home blood-collection device — a small patch on your arm with 30 microneedles thinner than an eyelash. Press a button, no pain, and in a minute or two it collects a small vial of blood. Ship it to a lab in New Jersey for a full panel of 50 biomarkers.

The same panel at Quest or LabCorp runs $1,000–2,000 out of pocket. Online competitors charge $300–500. Dudum's goal is to give it away free as a HIMS membership perk. This requires hundreds of millions of dollars in vertical integration across device, lab, and fulfillment — but he treats it as a loss leader. Don't make money on the test; use the data and trust to create long-term value.

Dudum told a story. A close friend, early 30s, health-conscious — runs regularly, watches his cholesterol. Routine numbers were slightly off, so he started eating more salmon and exercising more. But Dudum asked if he'd ever tested his Lp(a) — a genetic risk marker for cardiovascular disease. The friend got tested: 450. Normal is below 70. His father died of heart disease at 60. His grandfather at 55. Routine physicals never tested for it. Had he known that number earlier, he could have started far more aggressive treatment right away. That's what Dudum wants to give away for free.

Cancer Screening Is Becoming Affordable

HIMS partnered with Grail to bring the Galleri early cancer detection blood test to the platform at around $600. The test screens for roughly 50 types of cancer and is especially effective at catching hard-to-detect varieties like prostate, pancreatic, and ovarian cancer. Dudum's own father was diagnosed with stage IV colon cancer at 39 — the subsequent surgeries and years of chemotherapy cost the healthcare system hundreds of thousands, possibly millions of dollars.

His goal is to make these tests as routine as a dental checkup — once a year, look for early protein markers or millimeter-scale tumor signals. A partnership with Prenuvo for full-body MRI has also been announced. Prenuvo's machines cost roughly $500,000 each, and scans currently run $1,000–1,500, but amortized over ten years, the price could eventually fall to $300 annually.

AI's Real Impact on the Business: Design and Customer Service. Everything Else Is Overhyped.

HIMS has about 2,000 employees, and Dudum expects that number to reach 2,000–3,000 by 2030. Roughly one million square feet of pharmacy fulfillment requires significant frontline labor — pharmacist oversight, prescription review, drug dispensing — roles AI can't meaningfully replace.

Where AI is delivering massive leverage: customer service and engineering productivity (he thinks the impact elsewhere is overstated); design and creative work — the same team now produces three to four times the output, iterating on thousands of TV and Facebook ad variants dramatically faster; and on the clinical side, AI assists physicians with clinical decision-making and helps standardize care quality across thousands of doctors.

The $1.15 Billion Acquisition and the International Bet Behind It

HIMS went big on international expansion this year, acquiring three or four companies, including Australia's Eucalyptus for up to approximately $1.15 billion (including installments and earnouts). Dudum has known Eucalyptus founder Tim for four or five years. Tim initially operated across six or seven markets simultaneously — Indonesia, Japan, everywhere — all losing money. A year later he admitted most of it wasn't working and pulled back to focus. That willingness to experiment, admit failure, and adjust quickly impressed Dudum. Eucalyptus is now a market leader in Australia, the UK, and Germany, with Japan growing fast.

HIMS's U.S. cash flow funded the acquisition with minimal dilution — essentially paid from the balance sheet over the next few years. Dudum admits the aggressive pace is nerve-wracking, but he draws an analogy from high school rowing: the crew willing to endure the most discomfort and pain wins the race. His team has learned to keep operating inside that discomfort.

America's Food Industry Is the Root of Its Healthcare Crisis

Dudum's wife is French. In a French supermarket, the ingredient list for potato chips reads: potatoes and olive oil. At a U.S. Safeway, the same product has 40 ingredients. His three boys can demolish a box of organic blueberries in 15 seconds at breakfast — about $7 a box in San Francisco. The cost of eating healthy is a real burden for ordinary families.

He supports the current U.S. administration's push on food regulation — requiring companies to disclose ingredients, restricting ultra-processed foods and corn syrup. He believes the food industry is unquestionably the central driver of the obesity epidemic, and likely a contributor to the mental health crisis as well.

The Healthcare System Has Only One Right Incentive: The Patient Gets Better

Almost nothing in the current U.S. healthcare system ties incentives to patient outcomes. Everyone makes money, but nobody's revenue depends on whether the patient actually got healthier. HIMS works differently: users pay directly, and if they don't feel healthier and happier, they stop paying. So the company's incentives are naturally aligned with the user's — behind the scenes, it fights with drugmakers and diagnostics companies for the best products at the lowest prices.

Dudum believes the next five years will bring a fundamental shift in U.S. healthcare distribution: away from the byzantine chain of PBMs and insurers, toward direct-to-consumer platforms — on-demand consultations, transparent pricing, freedom to choose your doctor and treatment plan. Food delivery, financial services, and retail have all already made this transition. Healthcare is the largest, most important, most expensive industry in the country — and the last one to change.